Actarit is widely regarded as a safe and effective drug for the treatment of rheumatoid arthritis. There is no report on the bioproductin of actarit so far. In this study, we demonstrated for the first time the development of an artificial actarit biosynthetic pathway in Escherichia coli. First, 4-aminophenylacetic acid is selected as precursor substrates for the production of actarit. Second, an N-acetyltransferase that can efficiently catalyse the esterification of acetyl-CoA and 4-aminophenylacetic acid to form actarit was discovered. Subsequently, an engineered E. coli that allows production of actarit from simple carbon sources was established. Finally, we further increased the production of actarit to 206 ± 16.9 mg/L by overexpression of shikimate dehydrogenase ydiB and shikimate kinase aroK.

Actarit被广泛认为是治疗类风湿性关节炎的安全有效药物。目前还没有关于actarit生物制品的报道。在这项研究中，我们首次展示了在大肠杆菌中开发人工actarit 生物合成途径。首先，选择4-氨基苯乙酸作为生产actarit的前体底物。其次，发现了一种可以有效催化乙酰辅酶A和4-氨基苯乙酸酯化形成actarit的N-乙酰转移酶。随后，一种工程化的大肠杆菌建立了允许从简单的碳源生产actarit。最后，我们通过莽草酸脱氢酶 ydiB 和莽草酸激酶 aroK 的过表达，进一步将 actarit 的产量提高到 206 ± 16.9 mg/L。